BACKGROUND:Breast cancer stem cels are relatively special cels in the body, which have the self-renewal and multi-differentiation ability to promote tumor formation and development, and maintain tumor growth for a long-term. Therefore, it is of great significance to analyze the expression of resistance proteins of breast cancer stem cels. OBJECTIVE:To isolate breast cancer stem cels from human breast cancer tissues, to observe their differentiation and morphology characteristics and to analyze their resistance proteins. METHODS:Thirty tumor samples of breast invasive ductal carcinoma were selected to separate single cel suspension using mechanical separation method, and breast cancer stem cels and differentiated cels were sorted with two-step immunomagnetic bead method. Two-step immunocytochemistry method was used to detect the expression of resistance proteins in breast cancer stem cels. RESULTS AND CONCLUSION:Percentage of breast cancer stem cels had no significant correlations with age, long diameter of the tumor, lymph node metastasis and histological grading (P > 0.05). P-gp and GST-π positive rates in the breast cancer stem cels were significantly higher than those in the differentiated cels (P < 0.05); while TopoII and LRP positive rates in the breast cancer stem cels were significantly lower than those in the differentiated cels (P < 0.05). To conclude, breast cancer stem cels show stronger drug resistance than the differentiated cels by highly expressing P-gp and GST-π and lowly expressing TopoII and LRP, which may be the key reason for chemotherapy resistance in breast cancer.%背景：乳腺癌干细胞是人体内相对比较特殊的细胞，该细胞具有自我更新以及多向分化能力，能够促进肿瘤的形成和发展，并且长期维持肿瘤生长。因此，分析并研究乳腺癌干细胞耐药蛋白的表达具有重要的意义。目的：从人乳腺癌原代组织中分离乳腺癌干细胞，观察其分化及形态学特点，分析乳腺癌干细胞相关耐药蛋白的表达及意义。 方法：选取30例乳腺浸润性导管癌肿瘤组织标本，采用机械分离方法制作成不同的单细胞悬液，用免疫磁珠两步法分离出乳腺癌干细胞和乳腺癌分化细胞，采用免疫细胞化学二步法检测细胞耐药性蛋白的表达。 结果与结论：乳腺癌干细胞比例与患者的年龄、肿瘤的长径、淋巴结转移及组织学分级等差异不显著(P >0.05)；乳腺癌干细胞P-gp、GST-π阳性表达率显著高于乳腺癌分化细胞(P <0.05)；乳腺癌干细胞TopoⅡ、LRP阳性表达率显著低于乳腺癌分化细胞(P <0.05)，与乳腺癌分化细胞相比，乳腺癌干细胞可通过高表达P-gp，GST-π，低表达TopoⅡ，LRP而具有更强的耐药性，可能是乳腺癌化疗耐药的关键原因。
展开▼
